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Somatic Activating PIK3CA Mutations Cause Venous Malformation
Nisha Limaye,1 Jaakko Kangas,2,6 Antonella Mendola,1,6 Catherine Godfraind,3,4 Matthieu J. Schlo¨gel,1
Raphael Helaers,1 Lauri Eklund,2 Laurence M. Boon,1,5 and Miikka Vikkula1,*
Somatic mutations in TEK, the gene encoding endothelial cell tyrosine kinase receptor TIE2, cause more than half of sporadically occur-
ring unifocal venous malformations (VMs). Here, we report that somatic mutations in PIK3CA, the gene encoding the catalytic p110a
subunit of PI3K, cause 54% (27 out of 50) of VMs with no detected TEKmutation. The hotspot mutations c.1624G>A, c.1633G>A, and
c.3140A>G (p.Glu542Lys, p.Glu545Lys, and p.His1047Arg), frequent in PIK3CA-associated cancers, overgrowth syndromes, and
lymphatic malformation (LM), account for >92% of individuals who carry mutations. Like VM-causative mutations in TEK, the PIK3CA
mutations cause chronic activation of AKT, dysregulation of certain important angiogenic factors, and abnormal endothelial cell
morphology when expressed in human umbilical vein endothelial cells (HUVECs). The p110a-specific inhibitor BYL719 restores all
abnormal phenotypes tested, in PIK3CA- as well as TEK-mutant HUVECs, demonstrating that they operate via the same pathogenic
pathways. Nevertheless, significant genotype-phenotype correlations in lesion localization and histology are observed between individ-
uals with mutations in PIK3CA versus TEK, pointing to gene-specific effects.Venous malformations (VMs) are localized developmental
defects composed of ectatic venous channels with a thin
endothelial cell (EC) lining, surrounded by sparse, errati-
cally distributed vascular smooth muscle cells (vSMCs)
and a disorganized extracellular matrix (ECM).1,2 VMs
cause aesthetic problems, chronic and significant pain,
and obstruction of organ function as a result of their size
or localization. Currently, they are treated with surgery,
sclerotherapy, or both; however, these approaches have
significant limitations, including inaccessibility of lesions
and regrowth after incomplete resection.1
We discovered that activating mutations in TEK, the
gene encoding the EC tyrosine kinase receptor TIE2
(MIM 600221), cause familial3,4 (MIM 600195) as well as
sporadically occurring VMs,5,6 and downstream PI3K/
AKT signaling represents a major effector mechanism in
lesion formation.2,7,8 This led to the first evidence-based
application of molecular therapy to VMs: inhibition of
the PI3K/AKT pathway by the mTOR inhibitor rapamycin
(sirolimus) proved effective in ameliorating disease in a
mouse model as well as a pilot cohort of individuals with
difficult-to-treat VMs.8
PI3K signaling is initiated by binding of the p85 regula-
tory subunit to phosphorylated tyrosine residues of ligand-
activated receptors, allowing for the activation of the p110
catalytic subunit.9 Chronic PI3K/AKT activation can
instead occur as a result of somatic mutations in PIK3CA
(the gene encoding p110a, a class IA PI3K catalytic protein;
MIM 171834). Such mutations have been identified in a
wide variety of cancers10,11 (Catalogue of Somatic Muta-
tions in Cancer; COSMIC); in overgrowth syndromes,12–16
some of which (congenital lipomatous overgrowth with
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have a vascular component;19 and in lymphatic malforma-
tion (LM18,20,21). Given the pivotal role of PI3K activation in
VM causation, we hypothesized that PIK3CA mutations
might cause VMs that lack detectable TIE2 alterations.5,6
We screened surgically excised VMs from 87 unrelated
individuals with unifocal VM. Informed consent was ob-
tained from all participants, as approved by the ethics com-
mittee of the Faculty of Medicine at Universite´ Catholique
de Louvain. Tissues were collected in liquid nitrogen
immediately after surgical excision, performed for reasons
of medical necessity only. Frozen tissue homogenization
was followed by overnight digestion with 100 mg/ml Pro-
teinase K at 56 and DNA extraction (Wizard Genomic
DNA extraction kit, Promega). Targeted deep sequencing
of the 23 TEK and 20 PIK3CA coding exons (with ten nu-
cleotides of flanking introns each) was carried out with
an Ion AmpliSeq Custom DNA Panel (Life Technologies),
which consists of primers for multiplexed PCR amplifica-
tion of regions of interest (100% coverage of TEK;
98.75% coverage, missing 11 nucleotides in and flanking
exon 5 and 34 nucleotides in exon 20, of PIK3CA). Ion
Ampliseq libraries (with unique molecular bar codes and
universal priming sequences ligated to each PCR-amplified
sample according to manufacturers’ instructions) were
pooled, loaded onto an Ion 316 Chip V2, and sequenced
on an Ion PGM (all from Life Technologies) according to
manufacturers’ instructions. Raw sequences (FASTQ files)
were separated by bar code and aligned to the human
genome reference sequence (assembly GRCh37/hg19) by
the Torrent Server (Life Technologies). Aligned sequence
(BAM) files were submitted to the Torrent Variant Callerain, 1200 Brussels, Belgium; 2Oulu Center for Cell-Matrix Research, Faculty
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Table 1. Somatic Mutations Identified in Individuals with Unifocal VM
Study
TEK Mutation Detected
PIK3CA Mutation
Detected
TEK, PIK3CA Mutation
Not Detected Total Screened
c.2740C>T
(p.Leu914Phe) Other Total
Limaye et al., 20095 24 2 26 - - -
Soblet et al., 20136 9 8 17 - - -
Current study 26 11 37 27 23a -
Total (percent of total
screened)
59 (73.8%b) 21 (26.2%b) 80 (61.5%) 27 (20.8%) 23 (17.7%) 130
aAll samples without a detected TEK mutation from previous studies (by Sanger-sequencing of tissue cDNA5,6) were included in the current study.
bPercent of samples with a TEK mutation.for variant calling (Life Technologies). Called variants were
subsequently annotated, filtered, and visualized with
Highlander, an in-house bioinformatics framework.
The following quality-control criteria were used in call-
ing a sample positive for a variant: (1) total coverage depth
of R100 reads across the position; (2) R5 mutant reads,
including both forward and reverse orientation reads;
and (3)R1% mutant read frequency. Variants that passed
these criteria were evaluated as follows: (1) synonymous
variants were discarded; (2) variants present at >1% fre-
quency in databases of known polymorphisms (1000 Ge-
nomes, Genome of the Netherlands [GoNL], NHLBI
Exome Sequencing Project (ESP 2500 and 6500), and
Exome Aggregation Consortium [ExAC]) were discarded.
Novel missense mutations were submitted to six programs
(Polyphen2; SIFT; Mutation Taster; Mutation Assessor;
Functional Analysis though Hidden Markov Models, or
FATHMM; and Likelihood Ratio Test, or LRT; all imple-
mented in Highlander) for their predicted effect on protein
function.
We identified PIK3CAmutations in affected tissues from
27 out of 87 screened individuals (31%), and we identified
TEK mutations in 37 individuals (Table 1). When com-
bined with previously published data,5,6 mutations in
TEK account for 80 out of 130 (61.5%) individuals with
unifocal VM (Table 1); c.2740C>T (NM_000459.4;
p.Leu914Phe) remains the most frequent mutation (74%;
Table 1). PIK3CA mutations account overall for 27 out of
130 individuals with unifocal VM (20.8%; Table 1).
Five PIK3CA mutations were detected, at allele fre-
quencies ranging from 1% to 17.5% of total reads (Figure 1,p85α BD Ras BD C2 Helical
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The AmericanTable S1). ‘‘Hotspot’’ mutations (the most recurrent muta-
tions in PIK3CA-associated cancers and developmental dis-
orders) were identified in 25 out of the 27 individuals with
PIK3CA mutations (Figure 1): The p110 a-helical-domain
substitutions p.Glu542Lys (c.1624G>A, NM_006218.2)
and p.Glu545Lys (c.1633G>A) were identified in eight
and four individuals, respectively (together, 44.4%). The
kinase domain substitution p.His1047Arg (c.3140A>G)
was identified in 13 individuals (48.1%). p.Gly118Asp
(c.353G>A) and p.Gln546His (c.1638G>T), both present
in the COSMIC database, were identified in one individual
each (Figure 1, Table S1). p.Gly118Asp is predicted to be
damaging to protein function by six out of six in silico pre-
diction programs, and p.Gln546His is predicted to be
damaging by 3 out of 6 programs.
Targeted deep sequencing was performed on all available
blood DNA from individuals with PIK3CAmutations iden-
tified in lesions. Blood DNA from an individual was consid-
ered positive for the variant detected in the corresponding
tissue if (1) the variant was present inR5 reads, (2) the to-
tal read depth wasR100 reads, and (3) the variant was de-
tected at R3 SDs above the mean background frequency,
calculated separately for each variant position, as described
in Table S1.
PIK3CAmutations were not detected in affected individ-
uals’ blood DNA, despite coverage depths ranging from
383–11,384 reads (mean: 4,940) across the five mutation
positions (Table S1). Added to the relatively low frequency
of mutant alleles detected in tissues (Table S1), this sug-
gests that VM-causative PIK3CA mutations are indeed
somatic.Kinase
1068
p.His1047Arg
(n=13, 48.2%)
Figure 1. Distribution of Amino Acid
Changes and Frequency of PIK3CA So-
matic Mutations in Unifocal VM-Affected
Individuals
PIK3CA protein domains with mutations
identified and their frequency (percentage)
among individuals with somatic PIK3CA
mutations. Abbreviations are as follows:
n, number of individuals; BD, binding
domain.
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Figure 2. VM Localization in Individuals
with Mutations Detected in TEK, PIK3CA,
or Neither
Single, extensive slow-flowmalformations,
present at birth and growing proportion-
ately with individual. Lesions are bluish
and compressible. They can be cutaneous
(A and B), sub-cutaneous (A and B, arrows;
D), mucosal (C), or extended deep into
muscles (intra-muscular), joints (intra-
articular, (D) or other tissues and organs.
(A and B) Skin involvement; (C, D) no
skin involvement. (E) Number of VMs
with a mutation detected in TEK, PIK3CA,
or neither (N.D.: none detected) that do
or do not show skin involvement (p <
0.0001 overall, chi-square test). Inter-
group p values: post-hoc Fisher’s exact
tests.VMs are often cutaneous (Figures 2A and 2B), subcutane-
ous (Figures 2A and 2B), or mucosal (Figure 2C) and can
extend deep into various tissues and organs, such as mus-
cles, joints (Figure 2D), and intestines. We observed that
in subjects with TEK mutations (n ¼ 37 identified in this
study; Table 1), VMs often affected, but were not restricted
to, the skin (24 out of 36 individuals for whom informa-
tion on lesion localization was available; 66.7%). By
contrast, of the 23 (out of 27) PIK3CA-associated VMs
with available localization information, none showed
skin involvement (Figure 2C). This suggests that, unlike
TEK-associated VMs, PIK3CA-associated VMs tend not to
extend to the skin surface, perhaps as result of differences
in where and when these mutations were acquired.
VMs, uniquely among vascular anomalies, are associated
with significant coagulopathy in the form of high D-dimer
levels, sometimes accompanied by low fibrinogen
levels.1,22,23 We found that D-dimer levels were signifi-
cantly lower in individualswith no detectedTEK or PIK3CA
mutations than in individuals with mutations in either
gene (Figure S1). D-dimer levels have been correlated with
total lesion size;22 this might therefore simply reflect differ-
ences in the surface area, depth, or volume of VMs caused
by TEK and PIK3CA mutations, as compared to those of
as-yet-unknown cause. Alternatively, it could be due to dys-
regulation of coagulation cascade components in the endo-
thelium; we demonstrate that such effects can be engen-
dered by TEK2 and PIK3CA mutations (current study) in
human umbilical vein endothelial cells (HUVECs).
Blinded histological evaluation of hematoxylin and
eosin-stained formalin-fixed and paraffin-embedded tissue
sections from 36 unifocal VMs revealed four distinct cate-
gories (Figure 3A): the majority (n¼ 24), placed in category
I, consisted of isolated or interconnected veins with large,
highly irregular lumens and thick fibrotic walls containing
irregularly distributed clumps of vSMCs running parallel to
the ECs; their characteristics corresponding to the ‘‘classic’’
histological description of the malformation. Eight VMs,
placed in category II, were similar to VMs observed in
PTEN hamartoma tumor syndrome (PHTS; MIM 601728)916 The American Journal of Human Genetics 97, 914–921, Decembandwere characterizedby interconnected veinswithfibrotic
walls containing foci of lymphoid cells and vSMCs radiating
outward in irregular bundles perpendicular to the lumen.
The minority of VMs were placed in categories III (n ¼ 2)
and IV (n ¼ 2), both characterized by small, dilated veins
with thick walls composed of regular layers of vSMCs. Veins
in category III were isolated, whereas those in category IV
were smaller and clustered together; individual lumens
were separated by fibrous tissue, and a thick vSMC layer
bordered the entire cluster. 18 out of 21 tissueswithTEKmu-
tations (75%) were in category I, whereas only two were in
category II and only 1was in category III. In contrast, tissues
with PIK3CA mutations were equally distributed between
categories I and II (three and four out of seven, respectively),
and nonewere in categories III or IV. Intriguingly, categories
III and IV were almost exclusively made up of samples with
no detected TEK and PIK3CA mutation. Samples without a
detected mutation also included three tissues in category I
and two in category II (Figure 3E).
We previously showed that TEK mutations cause cell-
intrinsic alterations when expressed in HUVECs2,5,8 and
that activation of PI3K/AKT is a universal feature of
HUVECs expressing mutated TEK.2,7 We hypothesized
that, because PIK3CA encodes themajor isoformmediating
growth-factor-induced PI3K activation in ECs,24 PIK3CA
mutations have similar effects. HUVECs were retrovirally
transfected with PIK3CA wild-type or recurrent VM-causa-
tive mutant forms (c.1624G>A, c.1633G>A, and
c.3140A>G [p.Glu542Lys, p.Glu545Lys, and p.Hi-
s1047Arg]) in the pMXs-puro vector.27 Similar to the most
common VM-causative mutant, TEK c.2740C>T (TIE2
p.Leu914Phe2,7,8), PIK3CA variants activated AKT
(Figure 4A), disrupted normal EC-characteristic monolayer
morphology as visualized by phase-contrast microscopy
(Figure 4B), resulted in loss of ECM fibronectin
(Figure 4C), and strongly downregulated ANGPT2 and
PDGF-BmRNA expression asmeasured by real-time quanti-
tative PCR with normalization to GAPDH (Figure 4D). Plas-
minogen system-components were also somewhat dysre-
gulated by PIK3CA variants (Figure 4D). Inhibition ofer 3, 2015
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Figure 3. Histological Categorization of
Unifocal VM Tissues
(A) Hematoxylin and eosin-stained sec-
tions demonstrating the major features of
four histological categories identified.
(I) Interconnected (top) or isolated (bot-
tom) veins with large, irregular lumens (as-
terisks) and thick fibrotic walls (arrows)
containing irregular vascular smooth-mus-
cle-cell aggregates (not visible at this
magnification) oriented in parallel with
ECs; (II) interconnected veins (asterisks)
with fibrotic walls containing radial
bundles of vascular smooth-muscle cells
(arrow) and foci of lymphoid cells (arrow-
heads); (III, IV) small-to-medium sized
dilated veins (asterisks) with thick walls
composed of organized layers of vascular
smooth-muscle cells (arrows), either iso-
lated (III) or clustered with fibrous tissue
separating lumens (IV).
(B) Number of samples with a mutation detected in TEK, PIK3CA, or neither (N.D.: none detected) in each histological category (p ¼
0.005 overall, chi-square test). Inter-group p values: post-hoc chi-square tests.PIK3CA with BYL7129, which selectively targets p110a,25
abolished both PIK3CA-variant and TIE2-p.Leu914Phe-
induced AKT phosphorylation (Figure 5A), indicating that
these proteins participate in the same signaling pathway.
In addition, PIK3CA inhibition restored cell morphology
(Figures 5C and 5D) and ECM fibronectin levels
(Figure 5E) in both PIK3CA- and TIE2-p.Leu914Phe vari-
ants. Collectively, these data indicate that TIE2 and PIK3CA
variants induce the sameVM-causative signalingpathways.
Interestingly, unlike TIE2-p.Leu914Phe,2,7 PIK3CA vari-
ants induced low levels of pSTAT1 when they were
compared to the wild-type, and they induced no
pERK1/2 (Figure 4A). Added to the phenotypic differences
observed between individuals with TEK versus PIK3CAmu-
tations, this suggests certain gene-specific features that are
yet to be understood.
Rapamycin, probably because of its inhibitory effect on
AKT phosphorylation, was shown to control VM growth
in a murine transplantation model, and it had therapeutic
benefits in a clinical pilot study of six individuals (five
with VM and one with KTS).8 Three individuals with VM
had aTEKmutation,8 and the remaining three (one individ-
ual with KTS and individuals 10 and 57 with VMs; Table S1)
were found to have a PIK3CA mutation. We compared the
effects of BYL719 and rapamycin on abnormal HUVEC
phenotypes. Rapamycin diminished AKT phosphorylation
but did not restore ECM fibronectin to wild-type levels in
PIK3CA-variant or TIE2-p.Leu914Phe HUVECs (Figures 5B
and 5E). Loss of the EC cobblestone pattern was not, how-
ever, rescued in either PIK3CA-variant or TIE2-p.Leu914Phe
HUVECs (Figure 5C). This could be because PI3K activa-
tion, in addition to leading to changes in the AKT/mTOR
pathway, leads to wider changes in kinase activity in path-
ways including MAPK and ErbB;26 only a subset of these
changes are probably reversed by rapamycin.
We previously showed that TIE2-mediated VMs from
mouse transplant models and affected individuals haveThe Americanfeatures (revealed by histology and electron microscopy)
that correspond well to HUVEC-intrinsic phenotypes
observed in vitro.2,8 These include an uneven endothelial
layer with prominent cellular elongations and abnormal
perivascular ECM characterized by a wide basement mem-
brane with randomly oriented, isolated collagen fibrils
and irregularly distributed vSMCs.2 Downregulation of
PDGF-B, which we demonstrated ex vivo in VM tissue sec-
tions from affected individuals,7 most likely contributes to
defective recruitment of vSMCs. Downregulation of
ANGPT2 might contribute to decreased sprouting (with
increased lumen expansion)2 by abnormal ECs, whereas
ECM alterations are associated with upregulation of serine
proteases, including tissue plasminogen activator (tPA/
PLAT) and urokinase-type plasminogen activator (uPA).2
Induction of the plasmin/plasminogen cascade (tPA and
uPA upregulation with Plasminogen Activator Inhibitor 1
(PAI1) downregulation2) might also contribute to
increased fibrinolysis and elevated levels of D-dimers in in-
dividuals with VM.1,22,23 PIK3CA inhibition reverses all
abnormal features of PIK3CA- and TIE2-variant HUVECs.
It therefore represents an attractive potential therapy for
TIE2- and PIK3CA-mediated disease, which together ac-
count for the majority (82%) of unifocal VMs.Accession Numbers
The accession number for the 108 sequences (TEK and PIK3CA
coding exons from 87 tissue samples and 21 blood samples) re-
ported in this paper is PRJEB11395, available at European Nucleo-
tide Archive.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.
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Figure 4. VM-Causative PIK3CA and TIE2 Variants Cause Similar Phenotypes in Transduced HUVECs
Full-length cDNAs encoding TIE2-WT and TIE2-Leu914Phe cloned into pMXs vector, full-length cDNAs for PIK3CA-WT cloned into
pMXs-puro retroviral vector,27 and mutations generated with the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) ac-
cording to the manufacturer’s protocol. 293-GPG-VSV-G viral packaging cells28 were transfected with Fugene HD transfection reagent
(Promega) to produce viruses. HUVECs were transduced with pMXs-puro-PIK3CA constructs or empty vector selected with 1 mg/ml pu-
romycin (Sigma) for 5 days. (A) Activation of signaling molecules by HUVECs retrovirally transduced to express variant and wild-type
proteins. A representative immunoblot from three independent experiments is shown.
(B) Elongated cell morphology with loss of cobblestone pattern in PIK3CA- and TIE2-variant HUVECs (the scale bar represents 50 mm).
(C) Loss of ECM fibronectin: representative immunoblot from three independent experiments. HUVECs were removed by washing with
0.05% Triton X-100 and 50mMNH4OH in PBS, followed by onewash with 50mMNH4OH and three washes with PBS. Lysis was carried
out with ECM lysis buffer (6.5M Urea, 9.1 mM Na2HPO4, 1.7 mM NaH2PO4, 1% NP-40, 0.25% Sodium Deoxycholate, 150 mM NaCl,
0.1% SDS, and 1 mM EDTA).
(D) Normalized n-fold change in gene expression measured by real-time quantitative PCR on HUVEC cDNA (means þ SD, *p < 0.05,
**p < 0.01, ***p < 0.001 versus PIK3CA-WT, ANOVA with Tukey’s post-hoc test). WT indicates wild-type.Acknowledgments
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Figure 5. Normalization of PIK3CA- and TIE2-Variant HUVEC Phenotypes by PIK3CA Inhibition
(A) Effect of PIK3CA (p110a) inhibitor BYL719 versus DMSO control on AKT and ERK1/2 phosphorylation in confluent PIK3CA- and
TIE2-variant cells at 24 hr in full-serum media; a representative immunoblot from two independent experiments is shown.
(B) Effect of mTOR inhibitor rapamycin versus DMSO control on AKT and ERK1/2 phosphorylation in confluent PIK3CA- and TIE2-
variant cells at 24 hr in full-serum media; a representative immunoblot from two independent experiments is shown.
(C and D) Effects of DMSO (control), BYL719, or rapamycin on cell morphology at 24 hr. Cell extensions (arrows) were quantitated from
digital images; representative images from four independent experiments are shown. The scale bar represents 50 mm. Three images per
dish were randomly captured with a phase-contrast microscope, and the number of thin cell extensions overlapping neighboring cells
was manually counted from digitalized images. The average number of extensions from three images was considered a single
(legend continued on next page)
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The URLs for data presented herein are as follows:
1000 Genomes, http://www.1000genomes.org/
COSMIC, http://cancer.sanger.ac.uk/cosmic
European Nucleotide Archive accession number, http://www.ebi.
ac.uk/ena/data/view/PRJEB11395
ExomeAggregation Consortium (ExAC), http://exac.broadinstitute.
org/
Functional Analysis though Hidden Markov Models (FATHMM),
http://fathmm.biocompute.org.uk/
Genome of the Netherlands (GoNL), http://www.nlgenome.nl/
Highlander, http://sites.uclouvain.be/highlander/
Mutation Assessor, http://mutationassessor.org/
Mutation Taster, http://www.mutationtaster.org/
NHLBI Exome Sequencing Project (ESP), http://evs.gs.washington.
edu/EVS/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
Polyphen2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.jcvi.org/References
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